 Connection
Yuki Fujiwara to Immunotherapy
This is a "connection" page, showing publications Yuki Fujiwara has written about Immunotherapy.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.918 |
|
|
|
-
Fujiwara Y, Komohara Y. Therapeutic Strategies Targeting CD163 and CD169 in Macrophages for Cancer. Pathol Int. 2025 Nov; 75(11):551-561.
Score: 0.163
-
Yokoi M, Murakami K, Yaguchi T, Chamoto K, Ozasa H, Yoshida H, Shirakashi M, Ito K, Komohara Y, Fujiwara Y, Yano H, Ogimoto T, Hira D, Terada T, Hirai T, Tsukamoto H. ICOS+CD4+ T cells define a high susceptibility to anti-PD-1 therapy-induced lung pathogenesis. JCI Insight. 2025 05 22; 10(10).
Score: 0.157
-
Komohara Y, Kurotaki D, Tsukamoto H, Miyasato Y, Yano H, Pan C, Yamamoto Y, Fujiwara Y. Involvement of protumor macrophages in breast cancer progression and characterization of macrophage phenotypes. Cancer Sci. 2023 Jun; 114(6):2220-2229.
Score: 0.136
-
Tsukamoto H, Komohara Y, Tomita Y, Miura Y, Motoshima T, Imamura K, Kimura T, Ikeda T, Fujiwara Y, Yano H, Kamba T, Sakagami T, Oshiumi H. Aging-associated and CD4 T-cell-dependent ectopic CXCL13 activation predisposes to anti-PD-1 therapy-induced adverse events. Proc Natl Acad Sci U S A. 2022 07 19; 119(29):e2205378119.
Score: 0.130
-
Fujiwara Y, Torphy RJ, Sun Y, Miller EN, Ho F, Borcherding N, Wu T, Torres RM, Zhang W, Schulick RD, Zhu Y. The GPR171 pathway suppresses T cell activation and limits antitumor immunity. Nat Commun. 2021 10 06; 12(1):5857.
Score: 0.123
-
Fukuda R, Fujiwara Y, Maruyama T, Komohara Y. CD169-positive macrophages in lymph nodes and the tumor microenvironment: harnessing their biology for clinical diagnosis and anticancer therapeutic strategies. Front Immunol. 2026; 17:1852700.
Score: 0.043
-
Tagayasu Y, Yamada R, Kanemitsu K, Kondo Y, Fujiwara Y, Tanizaki T, Itoyama R, Kitano Y, Hayashi H, Komohara Y, Iwatsuki M. Increased Infiltration of Tissue-Resident Memory T Cells Predicts a Good Response to Anti-PD-L1 Immunotherapy in Extrahepatic Cholangiocarcinoma. Pathobiology. 2026; 93(1):1-11.
Score: 0.040
-
Anami T, Pan C, Fujiwara Y, Komohara Y, Yano H, Saito Y, Sugimoto M, Wakita D, Motoshima T, Murakami Y, Yatsuda J, Takahashi N, Suzu S, Asano K, Tamada K, Kamba T. Dysfunction of sinus macrophages in tumor-bearing host induces resistance to immunotherapy. Cancer Sci. 2024 Jan; 115(1):59-69.
Score: 0.035
-
Torphy RJ, Sun Y, Lin R, Caffrey-Carr A, Fujiwara Y, Ho F, Miller EN, McCarter MD, Lyons TR, Schulick RD, Kedl RM, Zhu Y. GPR182 limits antitumor immunity via chemokine scavenging in mouse melanoma models. Nat Commun. 2022 01 10; 13(1):97.
Score: 0.031
-
Kosaka A, Ishibashi K, Nagato T, Kitamura H, Fujiwara Y, Yasuda S, Nagata M, Harabuchi S, Hayashi R, Yajima Y, Ohara K, Kumai T, Aoki N, Komohara Y, Oikawa K, Harabuchi Y, Kitada M, Kobayashi H, Ohkuri T. CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes. J Exp Med. 2021 11 01; 218(11).
Score: 0.031
-
Sun Y, Chen W, Torphy RJ, Yao S, Zhu G, Lin R, Lugano R, Miller EN, Fujiwara Y, Bian L, Zheng L, Anand S, Gao F, Zhang W, Ferrara SE, Goodspeed AE, Dimberg A, Wang XJ, Edil BH, Barnett CC, Schulick RD, Chen L, Zhu Y. Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy. Sci Transl Med. 2021 07 28; 13(604).
Score: 0.030
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|